We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Collagen Solutions Plc | LSE:COS | London | Ordinary Share | GB00B94T6Y14 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 6.625 | 6.25 | 7.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMCOS
RNS Number : 3580I
Collagen Solutions PLC
19 June 2017
Collagen Solutions Plc
(the "Company" or the "Group")
Notice of Results
Analyst briefing
Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, announces they will issue their preliminary results for the year ending 31 March 2017 on Tuesday, 11 July 2017.
A briefing for analysts will take place at the offices of Walbrook PR, 4 Lombard Street, London EC3V 9HD at 9.30am on Tuesday, 11 July 2017.
If you would like to register to attend or require further information, please contact Walbrook PR on 020 7933 8780 or email collagen@walbrookpr.com.
About Collagen Solutions:
Collagen Solutions Plc is a global supplier, developer, and manufacturer of medical grade collagen, tissues, and related medical devices and components for use in regenerative medicine, medical devices and in-vitro diagnostics and research. The Company is also expanding its range of biomaterials-based finished medical devices based on its internal and acquired intellectual property for commercialisation with partners via licensing and distribution arrangements, including ChondroMimetic, an osteochondral scaffold for repairing cartilage defects in the knee. The Company's products are used in a wide variety of applications including orthopaedics, cardiovascular, dental, plastic surgery, wound healing, neurology and urology.
For further information, please contact:
Collagen Solutions Plc Contact via Walbrook Jamal Rushdy, Chief Executive Officer Gill Black, Chief Financial Officer Cenkos Securities plc (Nominated Tel: 0207 397 8900 Adviser and Broker) Stephen Keys Steve Cox Walbrook PR Tel: 020 7933 8780 or collagen@walbrookpr.com Anna Dunphy Mob: 07876 741 001 Mike Wort Mob: 07900 608 002
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORSFFFEMFWSELM
(END) Dow Jones Newswires
June 19, 2017 02:00 ET (06:00 GMT)
1 Year Collagen Solutions Chart |
1 Month Collagen Solutions Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions